Arvelle Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersBasel, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arvelle Therapeutics does
Arvelle Therapeutics was a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, founded in 2019 by Mark Altmeyer, a biopharma executive with over 35 years of industry experience. The company was focused on developing innovative therapeutics for central nervous system (CNS) disorders, operating within the pharmaceutical R&D value chain from preclinical development through clinical milestones.
Arvelle was built as an asset-focused vehicle around a proprietary CNS pipeline, financed primarily through venture capital rather than commercial revenue. The company secured approximately $221.8 million across two financing rounds — a ~$179.1 million Series A in February 2019 led by EQT Life Sciences, and a ~$42.7 million follow-on in May 2020 — drawing a syndicate that included BPV Capital Management, Andera Partners, H.I.G. BioHealth Partners, KB Investment, F-Prime, and Novaquest Capital Management. With 51–100 employees and a Switzerland-based operating footprint, Arvelle's go-to-market strategy was oriented toward clinical advancement and value-inflection rather than commercial sales.
Within approximately two years of founding, Arvelle was acquired by Angelini Pharma, a strategic pharmaceutical operator, for $1 billion. This transaction delivered a full exit to investors and absorbed Arvelle's pipeline into Angelini's broader CNS-adjacent franchise. Post-acquisition, founder Mark Altmeyer departed to chair ReproNovo, and Arvelle ceased to operate as an independent entity.
Arvelle Therapeutics firmographics
Firmographics- Name
- Arvelle Therapeutics
- Legal name
- Arvelle Therapeutics
- Website
- https://arvelletx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Arvelle Therapeutics industry classification
Industry- Product category
- CNS Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Arvelle Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Arvelle Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Arvelle Therapeutics product offering
Product offeringCore offering
Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative CNS therapeutics. Founded in 2019 in Basel, Switzerland, the company built a development pipeline targeting central nervous system disorders and was acquired by Angelini Pharma for $1 billion within approximately two years of its founding, having secured $200 million in private financing prior to the acquisition.
Product overview
Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on fertility and women's health. The company operated in the pharmaceutical development space, with no software or technology products identified in the available source data.
Differentiator
Problem solved
Functional benefit
Products and services
- CNS Therapeutics Development Pipeline Clinical-stage development pipeline targeting central nervous system disorders; intended for eventual commercialization by pharmaceutical acquirers and partners serving neurology patients.
Companies that use Arvelle Therapeutics
Customer profileIdeal customer profiles1 record
Arvelle Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Arvelle Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Arvelle Therapeutics competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Arvelle Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arvelle Therapeutics leadership team
Management profileNumber of profiles
Arvelle Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arvelle Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arvelle Therapeutics
What does Arvelle Therapeutics do?
Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative CNS therapeutics. Founded in 2019 in Basel, Switzerland, the company built a development pipeline targeting central nervous system disorders and was acquired by Angelini Pharma for $1 billion within approximately two years of its founding, having secured $200 million in private financing prior to the acquisition.
Is Arvelle Therapeutics a public or private company?
Arvelle Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Arvelle Therapeutics founded?
Arvelle Therapeutics was founded in 2019. It employs 51 to 100 people.
Where is Arvelle Therapeutics based?
Arvelle Therapeutics is headquartered in Basel, Switzerland, in the Europe region.
Does Arvelle Therapeutics have an API?
No public API is recorded for Arvelle Therapeutics.
What industry is Arvelle Therapeutics in?
Arvelle Therapeutics's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.